0001104659-19-051596.txt : 20190926
0001104659-19-051596.hdr.sgml : 20190926
20190926183009
ACCESSION NUMBER: 0001104659-19-051596
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190924
FILED AS OF DATE: 20190926
DATE AS OF CHANGE: 20190926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRICE MICHAEL DENNIS
CENTRAL INDEX KEY: 0001247313
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17082
FILM NUMBER: 191119199
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVELION THERAPEUTICS INC.
CENTRAL INDEX KEY: 0000827809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O NORTON ROSE FULBRIGHT
STREET 2: 1800 - 510 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6B 0M3
BUSINESS PHONE: (877) 764-3131
MAIL ADDRESS:
STREET 1: C/O NORTON ROSE FULBRIGHT
STREET 2: 1800 - 510 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6B 0M3
FORMER COMPANY:
FORMER CONFORMED NAME: QLT INC/BC
DATE OF NAME CHANGE: 20000608
FORMER COMPANY:
FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC
DATE OF NAME CHANGE: 19960618
FORMER COMPANY:
FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC
DATE OF NAME CHANGE: 19941201
4
1
a4.xml
4
X0306
4
2019-09-24
0
0000827809
NOVELION THERAPEUTICS INC.
NVLN
0001247313
PRICE MICHAEL DENNIS
C/O NOVELION THERAPEUTICS INC.
1800-510 WEST GEORGIA STREET
VANCOUVER
A1
V6B 0M3
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Financial Officer
Common Stock
2019-09-24
4
F
0
3926
0.76
D
14111
D
The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. The vesting event occurred as the result of the acceleration of vesting on all outstanding equity awards under the Issuer's equity plans upon the closing of the previously announced transaction between, inter alia, the Issuer's operating subsidiary, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Amryt Pharma plc on September 24, 2019. As a result of the transaction, the Issuer was divested of Aegerion, which constituted a change of control or sale event under the Issuer's equity plans.
/s/ Michael Price
2019-09-26